The recent finding that the neuronal cadherin gene CDH2 confers a highly significant risk for canine compulsive disorder led us to investigate whether missense variants within the human ortholog CDH2 are associated with altered susceptibility to obsessive-compulsive disorder (OCD), Tourette disorder (TD) and related disorders. Exon resequencing of CDH2 in 320 individuals identified four non-synonymous single-nucleotide variants, which were subsequently genotyped in OCD probands, Tourette disorder probands and relatives, and healthy controls (total N ¼ 1161). None of the four variants was significantly associated with either OCD or TD. One variant, N706S, was found only in the OCD/TD groups, but not in controls. By examining clinical data, we found there were significant TD-related phenotype differences between those OCD probands with and without the N845S variant with regard to the co-occurrence of TD (Fisher's exact test P ¼ 0.014, OR ¼ 6.03). Both N706S and N845S variants conferred reduced CDH2 protein expression in transfected cells. Although our data provide no overall support for association of CDH2 rare variants in these disorders considered as single entities, the clinical features and severity of probands carrying the uncommon non-synonymous variants suggest that CDH2, along with other cadherin and cell adhesion genes, is an interesting gene to pursue as a plausible contributor to OCD, TD and related disorders with repetitive behaviors, including autism spectrum disorders.
INTRODUCTION
Obsessive-compulsive disorder (OCD) and Tourette disorder (TD) are chronic, severe neuropsychiatric disorders, commonly having an early age of onset and a significant genetic component as shown by family, twin, segregation and linkage studies. [1] [2] [3] [4] [5] [6] Compulsive, repetitive and tic/TD-like behaviors in rodent models have been associated with variants in single genes such as Sapap3 and Slitrk5. [7] [8] [9] [10] Recently, single-nucleotide polymorphisms (SNPs) within the canine neuronal cadherin gene (CDH2) were shown to confer a significant risk for canine compulsive disorder (CCD). 11 CCD shares many similarities with OCD: (a) both are characterized by repetitive, timeconsuming behaviors that cause distress and functional impairment; (b) both have at least partially genetic heritabilities; and (c) symptoms in both humans and dogs can be alleviated by behavioral therapy, administration of antidepressants or a combination of both therapies. 12, 13 CDH2 belongs to the cadherin gene family of cell-cell adhesion molecules, which function in early brain morphogenesis, synaptogenesis and synaptic plasticity, including synaptic vesicle trafficking in glutamatergic neurons. [14] [15] [16] [17] Other cadherin genes, including CDH8, CDH9 and CDH10, have recently been implicated in the etiology of autism spectrum disorders, which may also be characterized by repetitive and compulsive behaviors. [18] [19] [20] We hypothesized that variants in the human ortholog CDH2 could confer susceptibility to OCD and OCD spectrum disorders such as TD. To test this, we exon-sequenced CDH2 to identify non-synonymous SNPs in a sample of 160 healthy controls and 160 OCD probands from our National Institute of Mental Health (NIMH) Intramural Research Program's Laboratory DNA collection, 21 and subsequently performed genotyping of identified putatively functional SNPs in a total of 1161 individuals, including OCD probands (N ¼ 260), TD probands and their relatives (N ¼ 454), and healthy controls (N ¼ 447).
METHODS
Unrelated OCD probands (N ¼ 260) were evaluated with the Structured Clinical Interview for DSM-IV-TR (SCID), the Yale-Brown Obsessive Compulsive Scale (YBOCS) ratings and other measures as described previously. 21, 22 The mean ± SD of total YBOCS scores was 22.4 ± 0.5, and there were no subgroup differences for the different OCD subgroups considered (including the OCD subgroups with identified CDH2 variants). TD probands and relatives (N ¼ 454) were evaluated by an experienced child psychiatrist based upon TD-related rating scales, as described elsewhere. 23 Unrelated healthy volunteers (N ¼ 447) consisted of undergraduate students from a large public university who participated in a separate study of genes and personality in return for partial course credit; they were administered self-report scales for personality measures. Although the control group completed a battery of selfreport questionnaires, we cannot completely rule out the occurrence of OCD or TD as they did not complete a formal diagnostic interview. Additional details on proband and control samples have been described previously. [22] [23] [24] All studies were conducted under protocols approved by the Institutional Review Board at the NIMH Intramural Research Program (OCD probands), the Rutgers University Institutional Review Board (TD probands and relatives) and by the Human Subjects Committee at Florida State University (healthy controls). Written informed consent was obtained from all adult participants (or, at Rutgers, their legal guardians, with written assent for minors).
Genomic DNA was extracted from whole blood obtained through venipuncture or from saliva samples (Oragene discs; DNA Genotek, Ottawa, ON, Canada). Exon sequencing was carried out in an initial subsample of 160 healthy controls and 160 OCD probands by the National Institutes of Health (NIH) Intramural Sequencing Center (NISC) as described previously. 25 These samples plus the remaining OCD probands, TD probands and relatives, and healthy controls were subsequently genotyped for the four non-synonymous CDH2 variants identified by sequencing. Genotyping was performed using 5 0 -exonuclease TaqMan predesigned or custom assays under standard conditions: a total volume of 20 ml and 20 ng of genomic DNA were amplified in the presence of 1 Â PCR Master mix (Qiagen, Valencia, CA, USA) and 1 Â TaqMan Assay (Applied Biosystems, Foster City, CA, USA; assay identification numbers and primer/probe sequences, as well as sequencing primer sequences are available from the corresponding author). Thermocycling conditions were as follows: 95 1C Â 10 min, followed by 50 cycles (95 1C Â 10 s, 60 1C Â 30 s, fluorescence reading). The overall genotyping completion rate exceeded 97% for each assay. None of the SNPs deviated from HardyWeinberg equilibrium in OCD probands, TD probands and relatives, or controls as determined by contingency-table statistics (nominal P40.05; data not shown). Duplicate samples (at least 10% of all samples, randomly chosen for each of the four SNPs) and no-template controls consistently yielded expected results. Statistical analyses were performed using Fisher's exact test with significance set at Po0.05 in two-sided analyses.
To begin to evaluate the functionality of the two CDH2 variants of greatest interest, site-directed mutagenesis was used to generate the corresponding mutants for N706S and N845S using QuickChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) in the pCMV6-XL6 vector expressing human CDH2 (Origene, Rockville, MD, USA). For the N706 variant, 5 0 -TCCAACGGG-3 0 was mutated to 5 0 -TCCAGCGGG-3 0 ; for the N845S variant, 5 0 -GACAATGAC-3 0 was mutated to 5 0 -GACAGTGAC-3 0 . Bidirectional DNA sequence analysis was performed to confirm the mutagenesis procedure, as well as to discard any off effects on other regions of the constructs. HEK293 cells were grown and transfected under standard conditions. At 48 h after transfection, cells were harvested and protein extracts were obtained for western blot evaluations. Anti-N-cadherin was prepared by immunization of rabbits with the extracellular domain of N-cadherin, expressed and secreted into the media by HEK293 cells. Western blots were analyzed using ImageJ (NIH, Bethesda, MD, USA).
RESULTS
In the initial sample of healthy controls (N ¼ 160) and OCD probands (N ¼ 160), all 16 CDH2 exons (Ref Seq NM_001792.3) were successfully sequenced, except for the first exon, which could not be amplified despite several primer re-designs. Four non-synonymous SNPs, Ala118Thr (A118T), Val289Ile (V289I), Asn706Ser (N706S) and Asn845Ser (N845S), were identified in CDH2, two of them (V289I and N706S) being novel variants (Table 1 and Figure 1 ). These four variants were chosen for follow-up genotyping in the 'extended' sample of OCD (N ¼ 260), TD probands and relatives (N ¼ 454), and healthy controls (N ¼ 447).
One of the novel variants, N706S, located between the extracellular domain EC5 and the transmembrane region of CDH2 (Figure 1 ), occurred in three individuals: an OCD proband; a TD proband; and a sibling of a different, unrelated TD proband. The latter individual had motor and phonic tics, but did not meet full TD diagnostic criteria. Thus, N706S was found in 3/714 of the OCD/TD patients plus TD relatives sample and not in any of 447 controls; this difference was not statistically significant. Interestingly, these three individuals had unusual clinical features, as summarized in the Supplementary Material. In particular, the OCD proband with the N706S variant had extremely severe OCD (YBOCS rating of 32), rapid-cycling bipolar disorder as well as other distinctive features, including a family pedigree with multiple other neuropsychiatric problems, including schizophrenia (Supplementary Figure 1) . In silico analysis using PMut predicted N706S as 'pathologically relevant' . 26 The other novel variant, V289I, located in the extracellular domain EC2 of CDH2 (Figure 1 ), was found in three individuals: a single TD proband who also had attention deficit hyperactivity disorder (ADHD) and polysubstance abuse; a single, unrelated TD proband who had OCD, ADHD and anorexia nervosa, and a single healthy control. No statistically significant differences were found for V289I.
The frequency of the N845S variant, located in the cytoplasmic domain of CDH2 (Figure 1 ), was generally similar across the OCD probands (4.6%), TD probands (5.6%) and healthy control (4.3%) populations (NS). We then compared the OCD/TD probands with N845S to those without the variant. In the OCD subgroup (N ¼ 260) we found that of the 12 individuals (4.6%) with N845S, four (33.3%) (Figure 1 ), was found in 10.4% of OCD probands, 6.1% of TD probands and 7.6% of controls (NS). This variant was not associated with any SCID-assessed diagnostic group.
In the total sample of OCD probands, TD probands and relatives, as well as the healthy control group, there were no other differences in other comorbid disorders or demographic variables between those with or without the four CDH2 variants. Overall, among the TD probands, comorbid OCD or ADHD was diagnosed in 41% or 48%, respectively. Among the TD relatives, rates of TD, OCD or ADHD were 14%, 21% or 12%, respectively. Among the OCD probands, TD was present in 12% of the sample overall. (ADHD was not diagnostically evaluated in the OCD probands as it is not a component of the SCID adult evaluation.)
In the initial evaluations of the impact of the variants on N-cadherin functionality/activity, both N706S and N845S variants showed consistently, markedly reduced protein levels compared with wild-type CDH2 when transfected in HEK293 cells (47% and 42%, respectively), as shown in Figure 2 . DISCUSSION This is the first report on the exon sequencing of the neuronal cadherin gene CDH2, encoding N-cadherin in a large human sample and, to our knowledge, the first study of CDH2 in any human disorder, other than in vitro studies of human cancer cells. Sequencing of CDH2 confirmed the relatively low heterozygosity of two known missense variants, A118T and N845S. Further, we also identified two novel missense SNPs: N706S, located between the fifth extracellular domain and the transmembrane domain, and V289I within the second extracellular domain (Figure 1a) . None of the four missense variants was significantly associated with OCD or TD diagnoses per se. Of interest, N706S occurred only in two unrelated OCD and TD probands and an unrelated TD proband's sibling (with motor and phonic tics) and not in any of 447 controls, while N845S appears to be associated with OCD/TD-related subgroups.
Cadherins constitute a superfamily of adhesion molecules featuring an N-terminal tandem series of ectodomains, followed by a single anchoring transmembrane domain and a C-terminal cytoplasmic region (B150 amino acids) that links cadherins to the underlying cytoskeleton. In the case of CDH2/N-cadherin, this is via sequential binding of b-catenin to a-catenin and then through intermediates to actin. 15, 27, 28 N-cadherin is required for critical brain processes, including long-term potentiation, pre-to post-synaptic adhesion, dendritic spine elongation -thereby regulating glutamate receptor trafficking and neuronal migration. [29] [30] [31] [32] A bioinformatic prediction of the multiple functional associations for CDH2 is provided in Supplementary Figure 2 . 33 The CDH2 N845S variant lies in the highly conserved cytoplasmic domain. Loss of integrity of this domain leads to loss of adhesive function. [34] [35] [36] [37] [38] [39] [40] N845 is located in the 'interaction region 2' of the extended region through which N-cadherin interacts with b-catenin. 41 D846 forms a hydrogen bond with Y654 of b-catenin. Phosphorylation of Y654 by Src and other cytoplasmic kinases reduces the association of cadherins with b-catenin, resulting in dissociation of the cadherincatenin complex. Thus, the N845S mutation in N-cadherin appears well placed to modulate cadherin-b-catenin interactions. However, there have been no site-directed mutagenesis studies before our initial study presented here, suggesting that a restricted amino-acid change resulting from the N845S variant might result in impaired N-cadherin expression and/or stability.
The N706S variant lies in the short region of CDH2 connecting the extracellular domains of CDH2 to the transmembrane segment ( Figure 1 ). Our initial mutagenesis study presented here indicates that the N706S variant reduces CDH2 expression and/or stability. This variant lies very close to the proposed cleavage site of CDH2 by metalloproteinase ADAM10 (residues 714-715). The proteolytic cleavage by ADAM10 -as well as by PS1/g-secretase -is critically important for the roles of CDH2 in cell adhesion and cell signaling. 42, 43 In addition, a prior study showed that induced single aminoacid changes that disrupted self-assembly of the transmembrame region reduced E-cadherin cell-cell adhesiveness. 41 Thus, N706S, found in one OCD proband, an unrelated TD proband, and an unrelated TD proband's sibling with chronic tics, and in none of the 447 healthy controls in this study, may represent a very rare variant related to the complex OCD, TD as well as perhaps bipolar and other neuropsychiatric disorder phenotypes found in these individuals and at least one of their relatives. This finding is relevant in the case of TD, where bilineal transmission has been reported. 6 Despite its lack of association, N706S seems an interesting variant to be followed up in larger cohorts.
The V289I variant lies in the EC2 ectodomain. Although EC1 has been documented to be critical to the adhesional/appositional functions of cadherins across cell-cell connections such as synapses, less seems to be known about the functional role of EC2.
As noted above, other members of the cadherin gene families have recently been found to be associated with autism spectrum disorders, in which repetitive behaviors are frequently observed. [18] [19] [20] 44, 45 Protocadherins and other cadherins have also been studied as candidate risk genes, but generally in small samples (o100 patients) of schizophrenia, bipolar disorder and OCD patients. [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] In addition, some cadherins have been specifically identified in genome-wide association scans of ADHD, addiction and neuroticism personality features. [56] [57] [58] Of related interest, variants in CDH2 and other cadherins have been widely found to CDH2 variants in OCD and TD PR Moya et al be associated with various cancers 16, 59, 60 and, specifically, upregulated CDH2 has been associated with transepithelial spreading of melanoma and pancreatic cancer together with rapid recurrence of cancer. [61] [62] [63] In summary, although CDH2 is an attractive candidate gene based on the CCD study findings, 11 the present results suggest that these CDH2 variants are not disease-causing by themselves. Further studies are needed to clarify if N706S and N845S, identified in OCD and TD subgroups, may or may not be risk factors of interest in OCD/TD when investigated in larger cohorts. Also, future experiments are underway to better characterize the impact of N706S and N845S on N-cadherin functionality.
There are several limitations to this study. Our strategy was directed exclusively toward non-synonymous variants in CDH2, as they provide a 'fast-track' for functional characterization and interpretation of findings. However, genetic variation leading to a disorder might not necessarily be located in protein coding regions; it is known that very distant regulatory elements affecting gene expression can have a role in the etiology of disorders. Importantly, an overwhelming majority of human genetic variation comes from non-coding variants. 64 The relatively small sample size available for examination of the very rare CDH2 variants (N706S and V289I) and for N845S in OCD and TD subphenotypes calls for major replication studies before drawing conclusions. Also, the healthy controls provided only allele frequencies and not complete phenotypic information. Finally, genegene and gene-environment interactions are relevant to accurate genotype-phenotype associations. In particular, there is some evidence for environmental contributions to OCD onset, OCD severity and other features of OCD, including possible contributions from psychological trauma, head trauma and autoimmune reactions. 65 Further research using larger numbers of samples from rigorously phenotyped affected and control individuals will be helpful to evaluate the validity of increased risk for compulsive and related disorders conferred by CDH2 and other cadherins in neuropsychiatric disorders.
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